title: Influence of 6q22-23 on overall survival in primary central nervous system lymphoma. Analysis of North Central Cancer Treatment Group trials 86 72 52, 93 73 51 and 96 73 51.
authors.forename: Ellen R
authors.initials: ER
authors.lastname: McPhail
authors.forename: Mark E
authors.initials: ME
authors.lastname: Law
authors.forename: Paul A
authors.initials: PA
authors.lastname: Decker
authors.forename: Brian P
authors.initials: BP
authors.lastname: O'Neill
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D016543:Central Nervous System Neoplasms / Q000235:genetics*; D002872:Chromosome Deletion; D002896:Chromosomes, Human, Pair 6 / Q000235:genetics*; D017322:Clinical Trials, Phase II as Topic; D005260:Female; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D016019:Survival Analysis